47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

Key Takeaways Explain This Topic AI

Premenstrual Syndrome (PMS) involves cyclical physical and mild-to-moderate affective symptoms restricted to the luteal phase that remit within a few days of menses onset, followed by a symptom-free follicular phase; Premenstrual Dysphoric Disorder (PMDD) is a severe, disabling psychiatric variant affecting 3% to 5% of women.

DSM-5 diagnostic criteria for PMDD require at least 5 luteal-phase symptoms present during the final week before menses onset, improving within days of onset, and absent post-menses; at least ONE core emotional symptom must be present: marked affective lability, marked irritability/anger, markedly depressed mood/hopelessness, or marked anxiety/tension.

The mandatory gold standard for confirming a diagnosis of PMDD is prospective daily symptom charting across at least TWO consecutive menstrual cycles (using validated tools such as the Daily Record of Severity of Problems [DRSP]) to verify luteal-phase restriction and rule out underlying chronic mood disorders with premenstrual exacerbation.

Selective Serotonin Reuptake Inhibitors (SSRIs: fluoxetine, sertraline, paroxetine) represent the first-line pharmacotherapy for PMDD; unlike in MDD where therapeutic onset requires 4 to 6 weeks, SSRIs in PMDD provide rapid symptom relief within 24 to 48 hours due to allopregnanolone neurosteroid modulation of GABA-A receptors.

SSRIs in PMDD can be administered either continuously (daily) OR intermittently (luteal-phase dosing: started on cycle day 14 and stopped at the onset of menses); second-line therapy consists of continuous or 24/4 extended-cycle combined oral contraceptives containing Drospirenone (a spironolactone analogue with anti-mineralocorticoid properties; FDA-approved for PMDD).

Last updated: September 2026

Clinical Definitions & The Premenstrual Spectrum

Premenstrual disorders encompass a spectrum of cyclical physical, affective, and behavioral symptoms that recur specifically during the luteal phase of the ovulatory menstrual cycle and resolve rapidly following the onset of menses. Recognizing this spectrum is essential in primary care to prevent over-diagnosis, avoid inappropriate psychotropic prescribing, and validate genuine, severe functional disability.

The Premenstrual Continuum

Premenstrual Symptoms (Physiologic Premenstrual Changes) :

Experienced by up to 80% to 85% of ovulating women .

Mild, manageable physiological changes such as transient abdominal bloating, mild breast tenderness (mastalgia), mild fatigue, and specific food cravings (e.g., carbohydrates, chocolate).

These symptoms do not cause significant subjective distress, do not impair social or occupational functioning, and do not constitute a medical disorder.

Premenstrual Syndrome (PMS) :

Affects approximately 20% to 30% of women of reproductive age .

Characterized by at least one moderate physical symptom (bloating, breast swelling, headache) and at least one affective symptom (irritability, mood swings, anxiety) occurring regularly during the 5 to 7 days preceding menses.

Symptoms cause moderate subjective distress and modest social or interpersonal interference but do not severely incapacitate daily functioning. Follicular phase is completely symptom-free.

Premenstrual Dysphoric Disorder (PMDD) :

A severe, disabling psychiatric disorder recognized in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; under Depressive Disorders).

Affects 3% to 5% of menstruating females .

Dominated by profound affective and psychological destabilization (severe dysphoria, extreme irritability, explosive anger, affective lability, and interpersonal conflict) that causes marked impairment in social, occupational, or academic functioning.

Neurobiology & Pathophysiology: The Neurosteroid-GABA Axis

A critical clinical teaching point for board examinations and clinical practice is that PMDD is NOT an endocrine deficiency or hormone imbalance state .

Normal Gonadal Hormone Levels

Repeated clinical trials have demonstrated that circulating plasma concentrations of estrogen (17-beta estradiol), progesterone, and gonadotropins (LH, FSH) in women with severe PMDD are completely normal and indistinguishable from healthy, asymptomatic controls .

Women with PMDD do not produce excessive estrogen or inadequate progesterone; rather, they exhibit an abnormal neurobiological vulnerability and heightened central nervous system sensitivity to normal, physiological cyclical fluctuations of gonadal steroids. THE NEUROBIOLOGICAL CASCADE OF PMDD

• 1. Normal Ovulation occurs
• └── Corpus luteum synthesizes progesterone during the luteal phase
• └── Progesterone is metabolized across the blood-brain barrier into ALLOPREGNANOLONE

• 2. Allopregnanolone & The GABA-A Receptor
• └── Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors
• └── In healthy women: promotes calm, sedation, and anxiolytic tone
• └── In PMDD: altered GABA-A receptor subunit composition (alpha-4, beta-2, delta subunits)
• results in PARADOXICAL CNS EXCITATION, irritability, and anxiety in response to allopregnanolone

• 3. Luteal Phase Withdrawal
• └── Late luteal corpus luteum demise causes a precipitous PLUNGE in allopregnanolone levels
• └── Induces acute GABA-ergic withdrawal and central SEROTONERGIC HYPOFUNCTION
• └── Manifests clinically as severe affective lability, emotional outbursts, and dysphoria
• The Role of Central Serotonin Transmission

Estrogen and progesterone heavily modulate central serotonergic (5-HT) neurotransmission by regulating serotonin receptor expression, reuptake transporter density, and turnover.

Women with PMDD exhibit abnormal central serotonergic responsivity: during the luteal phase, central serotonin levels fall precipitously. This serotonin deficit mediates depressive mood, carbohydrate cravings, pain hypersensitivity, and loss of impulse control.

This direct biological link explains why Selective Serotonin Reuptake Inhibitors (SSRIs) provide immediate therapeutic efficacy.

DSM-5 Diagnostic Criteria for PMDD

To establish a formal diagnosis of PMDD under DSM-5 criteria, all of the following criteria (A through E) must be satisfied.

Criterion A: Symptom Timing & Requirements

In the majority of menstrual cycles over the preceding 12 months, at least 5 symptoms must be present in the final week before the onset of menses , start to improve within a few days after the onset of menses, and become minimal or entirely absent in the week post-menses (follicular phase) .

The Core Affective Symptoms (Must Have At Least ONE)

At least one of the following four core emotional symptoms must be present:

Marked affective lability (e.g., sudden tearfulness, mood swings, feeling suddenly overwhelmed, or heightened sensitivity to interpersonal rejection);

• Marked irritability or anger or increased interpersonal conflicts;
• Markedly depressed mood , feelings of hopelessness, or self-deprecating thoughts;

Marked anxiety, tension , and/or feelings of being "keyed up" or on edge.

Additional Symptoms (To Reach a Total of At Least Five)

One or more of the following symptoms must be present to reach the required total of 5 symptoms (when combined with core symptoms above):

• 5. Decreased interest in usual activities (work, school, hobbies, friends);
• 6. Subjective difficulty in concentration or mental fog;
• 7. Lethargy, easy fatigability , or marked lack of energy;
• 8. Marked change in appetite , overeating, or specific food cravings (particularly sugars/carbohydrates);
• 9. Hypersomnia or insomnia ;
• 10. A sense of being overwhelmed or out of control;

11. Physical symptoms such as breast tenderness or swelling, joint or muscle pain, sensation of bloating, or weight gain.

Criteria B, C, D, and E

Criterion B (Functional Impairment) : Symptoms are associated with clinically significant distress or interference with work, school, usual social activities, or interpersonal relationships (e.g., marital conflict, avoidance of social gatherings, missed workdays).

Criterion C (Differential Exclusion) : The disturbance is not merely an exacerbation of the symptoms of another psychiatric disorder, such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, or a personality disorder (although PMDD can co-exist with these disorders).

Criterion D (The Mandatory Confirmation) : Criterion A must be confirmed by prospective daily ratings during at least two consecutive symptomatic menstrual cycles .

Criterion E (Substance & Medical Exclusion) : The symptoms are not attributable to the physiological effects of a substance (substance abuse, medication side effect) or a general medical condition (e.g., hyperthyroidism, hypothyroidism).

The Mandatory Diagnostic Requirement: Prospective Daily Symptom Charting

Caution

CRITICAL CLINICAL MANDATE: NEVER DIAGNOSE PMDD RETROSPECTIVELY A clinician CANNOT definitively diagnose PMDD based solely on a patient's retrospective recall of symptoms during an initial clinic visit.

Studies reveal that up to 50% of women who report "severe PMS/PMDD" on retrospective recall do NOT actually have PMDD when tracked prospectively. Instead, many suffer from chronic underlying Major Depressive Disorder, Generalized Anxiety Disorder, or dysthymia with Premenstrual Exacerbation (PME) . Initiating targeted PMDD therapy without prospective confirmation risks mismanaging underlying psychiatric disease.

Validated Prospective Tracking Instruments

Daily Record of Severity of Problems (DRSP) : The gold-standard validated instrument. The patient rates the severity of 21 emotional and physical items on a daily Likert scale (1 = not at all, to 6 = extreme) every evening for at least two consecutive menstrual cycles .

Visual Analogue Scales (VAS) or Menstrual Symptom Calendars : Acceptable alternatives. PROSPECTIVE DAILY LOGGING: PMDD vs. PME vs. CHRONIC MDD

• Menstrual Phase PMDD Trajectory Premenstrual Exacerbation Chronic Major Depression
• (True Disorder) (PME of MDD or GAD) (No Cycle Link)
• ═══════════════════════════════════════════════════════════════════════════════════════════════════════════
• Follicular Phase COMPLETELY ASYMPTOMATIC Mild to Moderate Baseline Continuous, unremitting
• (Cycle Days 4 to 10) (Score: 1 / None) Depression or Anxiety Severe Depression

Ovulation (Day 14) Symptom-free Mild Baseline Symptoms Continuous Depression

• Late Luteal Phase EXPLOSIVE SYMPTOM ONSET SEVERE SPIKE in symptoms Moderate to Severe
• (Days -7 to -1) (Score: 5-6 / Severe) above chronic baseline Depression unchanged

• Menses Onset RAPID COMPLETE RESOLUTION Worsening remits to Persistent Depression
• (Days +1 to +3) within 48 to 72 hours baseline chronic symptoms continues throughout
• ═══════════════════════════════════════════════════════════════════════════════════════════════════════════
• Clinical Interpretation of the DRSP

True PMDD : Confirmed when daily charting demonstrates a >=30% increase in symptom severity during the 7 days prior to menses compared with the postmenstrual baseline (Cycle Days 4 to 10), accompanied by a completely symptom-free interval (follicular remission) .

Premenstrual Exacerbation (PME) : Diagnosed when symptoms worsen during the luteal phase but never resolve completely during the follicular phase . The patient retains persistent, low-to-moderate baseline depressive or anxiety symptoms during Days 4 through 10. Management requires treating the primary underlying major depression or anxiety disorder.

Differential Diagnosis & Medical Workup DIFFERENTIAL DIAGNOSIS & TRIAGE FOR PMDD

• Condition Distinguishing Clinical Features Diagnostic Workup
• ═══════════════════════════════════════════════════════════════════════════════════════════════════════
• Major Depressive Disorder Continuous, chronic depressed mood/anhedonia PHQ-9; prospective daily log
• / GAD persisting throughout follicular phase; no demonstrates absence of a

symptom-free window. symptom-free follicular window.

Perimenopausal Transition Irregular cycle frequency; hot flushes, night Serum FSH / estradiol (elevated

sweats, sleep fragmentation; age >40 to 45. FSH variable; clinical diagnosis).

Thyroid Dysfunction Hypothyroidism causes fatigue, weight gain, Serum TSH (mandatory screening

constipation, depression; hyperthyroidism test in all suspected cases).

causes anxiety, palpitations, irritability.

Substance / Alcohol Use Symptoms correlate with intoxication or CAGE / AUDIT-C screening;

Disorders withdrawal; no strict luteal restriction. targeted urine toxicology.

Dysmenorrhea / Severe pelvic pain, cramping, dyspareunia; Pelvic TVUS; pelvic exam;

Endometriosis lacks primary affective/psychological lability. dysmenorrhea peaks WITH flow.

═══════════════════════════════════════════════════════════════════════════════════════════════════════

Laboratory Evaluation : In every patient presenting with suspected PMS or PMDD, obtain a serum TSH to rule out occult thyroid disease. Additional testing (CBC, comprehensive metabolic panel) is guided by clinical suspicion.

First-Line Lifestyle & Behavioral Modifications

For mild premenstrual symptoms or as adjunctive therapy in confirmed PMDD:

Regular Aerobic Exercise : Engaging in >=150 minutes of moderate-intensity aerobic physical activity per week (e.g., brisk walking, jogging, swimming, cycling) increases central endorphin concentrations, reduces fatigue, improves premenstrual mood, and alleviates perceived abdominal bloating.

Dietary Modifications :

Complex Carbohydrates : Ingesting complex carbohydrates (whole grains, oats, legumes) promotes sustained, steady insulin release, which enhances cerebral tryptophan uptake and facilitates central serotonin synthesis, reducing luteal mood swings.

Restrict Sodium : Limiting dietary salt reduces extracellular fluid volume expansion, relieving breast swelling and peripheral edema.

Limit Refined Sugars, Caffeine & Alcohol : Caffeine exacerbates premenstrual anxiety, irritability, sleep disturbances, and fibrocystic breast tenderness. Alcohol worsens luteal emotional volatility and destabilizes sleep architecture.

Sleep Hygiene & Stress Management : Cognitive Behavioral Therapy (CBT) specifically adapted for premenstrual disorders has demonstrated substantial efficacy in reducing depressive cognitions and enhancing coping mechanisms.

Evidence-Based Nutritional Supplements :

Calcium Carbonate (1,200 mg PO daily) : Randomized controlled trials show a significant reduction in luteal emotional symptoms, food cravings, and water retention.

Pyridoxine (Vitamin B6; 50 to 100 mg PO daily) : Cofactor in serotonin and dopamine synthesis. Safety Alert : Do not exceed 100 mg/day due to the established risk of sensory peripheral neuropathy.

Magnesium (200 to 400 mg PO daily) : Reduces fluid retention, bloating, and menstrual migraines.

First-Line Pharmacotherapy: Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs represent the undisputed first-line pharmacotherapy for PMDD, supported by Category A evidence from numerous randomized double-blind placebo-controlled trials and Cochrane systematic reviews. FIRST-LINE SSRI REGIMENS FOR CONFIRMED PMDD

• Medication Continuous Daily Regimen Intermittent Luteal-Phase Regimen
• ═══════════════════════════════════════════════════════════════════════════════════════════════════════
• Fluoxetine* 20 mg PO once daily 20 mg PO daily starting on Cycle Day 14
• (titrate to max 40 mg) and discontinued at the onset of menses

• Sertraline* 50 to 100 mg PO once daily 50 to 100 mg PO daily starting on Cycle Day 14
• (titrate to max 150 mg) and discontinued at the onset of menses

• Paroxetine CR* 12.5 to 25 mg PO once daily 12.5 to 25 mg PO daily starting on Day 14
• (controlled-release) and discontinued at the onset of menses

• Escitalopram / 10 to 20 mg PO once daily 10 to 20 mg PO daily starting on Day 14
• Citalopram (off-lab)(titrate to max 20 mg) and discontinued at the onset of menses
• ═══════════════════════════════════════════════════════════════════════════════════════════════════════

*Note: Formulations formally approved by the US FDA specifically for the treatment of PMDD.

The Unique Pharmacodynamics of SSRIs in PMDD

Important

THE CRITICAL BOARD PEARL: RAPID SSRI ONSET IN PMDD A fundamental pharmacologic distinction exists between using SSRIs for Major Depressive Disorder versus PMDD:

Major Depressive Disorder : SSRIs require 4 to 6 weeks of continuous daily administration to downregulate somatodendritic 5-HT1A autoreceptors, increase synaptic serotonin, and stimulate hippocampal neurogenesis (BDNF transcription).

Premenstrual Dysphoric Disorder : SSRIs produce dramatic, robust symptom relief within 24 to 48 HOURS of administration !

Biological Mechanism : In PMDD, SSRIs do not rely on slow genomic transcription. Instead, SSRIs act via an acute, non-genomic allosteric mechanism that rapidly enhances the activity of the neurosteroid-synthesizing enzyme aldo-keto reductase (AKR1C2 / 5-alpha-reductase) . This rapidly normalizes limbic allopregnanolone levels, restoring normal inhibitory GABA-A receptor function within hours.

Intermittent (Luteal-Phase) vs. Continuous SSRI Dosing

Because SSRIs act within 24 to 48 hours in PMDD, clinicians can utilize two distinct dosing paradigms with equivalent clinical efficacy:

Intermittent Luteal-Phase Dosing :

The patient initiates the SSRI on Cycle Day 14 (or at the estimated time of ovulation) and takes it daily until the onset of menstrual bleeding (or 1-2 days after flow starts) , at which point the medication is stopped.

The patient takes NO medication during the entire follicular phase (Cycle Days 1 through 13).

Major Advantages :

• Reduces drug exposure by 50% across the patient's lifespan;
• Substantially reduces medication financial costs;

Prevents long-term chronic adverse effects, particularly persistent sexual dysfunction (anorgasmia, decreased libido) and weight gain ;

Discontinuation syndrome does not occur because of the brief duration of exposure.

Best candidates : Women with strictly regular, predictable menstrual cycles (e.g., 28-day cycles) and no baseline mood or anxiety symptoms.

Continuous Daily Dosing :

The patient takes the SSRI every single day of the month without interruption.

Best candidates : Women with irregular or unpredictable menstrual cycle lengths (where predicting Day 14 is impossible), women with co-existing mild baseline dysthymia/anxiety, or women who find starting and stopping medication confusing.

Symptom-Onset Dosing :

Initiating the SSRI on the very first day premenstrual symptoms manifest and stopping at menses onset. Effective in a subset of highly attuned patients with variable cycle lengths.

Second-Line & Hormonal Therapies: Drospirenone & GnRH Agonists

When SSRIs are ineffective, poorly tolerated (due to nausea, insomnia, or severe sexual side effects), or when the patient concurrently desires highly effective contraception, hormonal ovulation suppression is the next step.

Combined Oral Contraceptives Containing Drospirenone

Mechanism : Combined oral contraceptives (COCs) suppress the hypothalamic-pituitary-ovarian axis by providing negative feedback on pituitary LH and FSH secretion, thereby completely abolishing ovulation and preventing corpus luteum formation . Without a corpus luteum, cyclical progesterone and allopregnanolone surges are extinguished.

The Molecule: Drospirenone :

Drospirenone is a unique synthetic progestin derived from 17-alpha-spironolactone .

It possesses potent anti-mineralocorticoid activity (antagonizes aldosterone receptors, directly blocking sodium and water retention) and anti-androgenic activity .

Clinical Benefits : Effectively treats somatic water retention, abdominal bloating, cyclic weight gain, and mastalgia, while improving acne and hirsutism.

The FDA-Approved 24/4 Dosing Regimen :

Drospirenone 3 mg / Ethinyl Estradiol 20 mcg in a 24/4 regimen (24 active hormonal tablets followed by only 4 inactive placebo tablets; e.g., Yaz).

Why 24/4? Traditional 21/7 COC formulations feature a 7-day hormone-free interval, which allows endogenous follicular recruitment, transient hormone rises, and escape of distressing premenstrual symptoms. Shortening the hormone-free window to 4 days provides profound, stable hormonal suppression and superior PMDD symptom control.

Safety Warning : Drospirenone's anti-mineralocorticoid properties can cause mild potassium retention. Serum potassium should be monitored if co-administered with other potassium-sparing agents (ACE inhibitors, ARBs, potassium-sparing diuretics, daily NSAIDs).

Gonadotropin-Releasing Hormone (GnRH) Agonists

Mechanism : Continuous administration of a GnRH agonist produces initial transient pituitary stimulation followed by profound downregulation and desensitization of GnRH receptors , extinguishing LH and FSH secretion. This induces a state of reversible medical oophorectomy (chemical menopause) , completely eliminating cyclical gonadal steroid production.

Regimen :

Leuprolide depot (3.75 mg IM monthly) or Goserelin subcutaneous implant.

Mandatory "Add-Back" Therapy : Because profound hypoestrogenism causes rapid bone mineral density loss (osteopenia/osteoporosis) and severe vasomotor symptoms (hot flushes, vaginal atrophy), low-dose add-back hormone therapy is mandatory if treatment extends beyond 3 to 6 months:

Continuous low-dose oral 17-beta estradiol (1 mg daily) or transdermal estradiol patch (0.05 mg daily) combined with continuous oral medroxyprogesterone acetate (2.5 mg daily) or micronized progesterone (100 mg daily).

Indications : Reserved exclusively for severe, incapacitating PMDD that has failed maximized trials of both continuous/intermittent SSRIs and drospirenone-containing COCs.

Bilateral Oophorectomy (Definitive Surgical Extirpation)

Bilateral Salpingo-Oophorectomy (BSO), typically with concurrent hysterectomy, is a permanent, irreversible procedure of last resort.

Strict prerequisite: The patient must demonstrate complete, unambiguous symptom remission during a 3- to 6-month trial of GnRH agonist medical suppression to definitively prove that her psychiatric disability is driven by ovarian cyclicity before undergoing irreversible surgical castration.

Loading diagram... Comprehensive Diagnostic & Stepwise Management Algorithm for PMDD